• Biodel Inc., of Danbury, Conn., reported that enrollment has been completed in a Phase II study of its ultra-rapid-acting prandial insulin candidate BIOD-123. The study is evaluating the use of BIOD-123 vs. Humalog (insulin lispro, Eli Lilly and Co.) on measures of HbA1c, postprandial glucose excursions, glycemic variability, hypoglycemic event rates and weight changes in about 130 U.S. patients with Type 1 diabetes. Biodel expects to report top-line data from the trial in the third quarter.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter